LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JL
London, 19 December 2022 – LIfT BioSciences is pleased to announce that it’s lead investor, Starbloom Capital, has provided further...
top of page
Welcome to LIfT BioSciences
LIfT BioSciences is developing a breakthrough allogeneic innate cell therapy platform that produces different types of Immunomodulatory Alpha Neutrophils (IMANs). LIfT's focus is on producing an exceptional type of anti-cancer alpha neutrophil with enhanced cytotoxic and immunomodulatory properties.
Our mission is to develop affordable curative therapies for solid tumours with high unmet medical need.
bottom of page